We are live on
!
Find out more
Fate Therapeutics
FATE
FATE
159 hedge funds and large institutions have $362M invested in Fate Therapeutics in 2023 Q4 according to their latest regulatory filings, with 28 funds opening new positions, 42 increasing their positions, 59 reducing their positions, and 37 closing their positions.
New
Increased
Maintained
Reduced
Closed
153% more call options, than puts
Call options by funds: $101K | Put options by funds: $40K
78% more capital invested
Capital invested by funds: $203M → $362M (+$159M)
1.31% more ownership
Funds ownership: 96.88% → 98.19% (+1.3%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
6% less funds holding
Funds holding: 170 → 159 (-11)
24% less first-time investments, than exits
New positions opened: 28 | Existing positions closed: 37
29% less repeat investments, than reductions
Existing positions increased: 42 | Existing positions reduced: 59
Holders
159
Holders Change
-11
Holders Change %
-6.47%
% of All Funds
2.32%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.01%
New
28
Increased
42
Reduced
59
Closed
37
Calls
$101K
Puts
$40K
Net Calls
+$61K
Net Calls Change
+$88K
Top Buyers
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$8.06M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
+$4.01M |
| 3 |
Morgan Stanley
New York
|
+$2.86M |
| 4 |
IHAM
Integral Health Asset Management
New York
|
+$2.12M |
| 5 |
Citigroup
New York
|
+$1.97M |
Top Sellers
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$3.81M |
| 2 |
BlackRock
New York
|
-$3M |
| 3 |
Millennium Management
New York
|
-$2.76M |
| 4 |
D.E. Shaw & Co
New York
|
-$2.67M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$2.18M |
